This is just the start': Research into Covid-19 opens doors to understanding other diseases and conditions

新冠疾病研究为人类研究其他疾病打开门路，这仅仅是开端

The billions of dollars invested in covid vaccines and covid-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis, and far more diseases.

到目前为止在新冠疫苗和新冠疾病数十亿美元的投资，有望在未来几十年产生医学和科技红利，帮助医生治疗流感，癌症，囊肿性纤维化和更多的疾病

This is just the start," said Dr. Judith James, vice president of clinical affairs for the Oklahoma Medical Research Foundation. "We won't see these dividends in their full glory for years."

这仅仅是开端，数年之内我们还不能看到这些红利的全貌。

Building on the success of mRNA vaccines for covid, scientists hope to create mRNA-based vaccines against a host of pathogens, including influenza, Zika, rabies, HIV, and respiratory syncytial virus, or RSV, which hospitalizes 3 million children under age 5 each year worldwide.

基于新冠mRNA疫苗的成功，科学家希望开发一系列mRNA载体病原疫苗，包括流感，寨卡病毒，狂犬病，艾滋病和造成全球每年300万五岁以下儿童住院的呼吸道合胞体病毒

Researchers see promise in mRNA to treat cancer, cystic fibrosis, and rare, inherited metabolic disorders, although potential therapies are still many years away.

尽管潜在的治疗方法还要很多年，研究人员看到了mRNA 技术在治疗癌症，囊性纤维化，罕见疾病和遗传性代谢障碍的希望。

Predicting Which Covid Patients Are Most Likely to Die

Overturning Dogma

For decades, public health officials created policies based on the assumption that viruses spread in one of two ways: either through the air, like measles and tuberculosis, or through heavy, wet droplets that spray from our mouths and noses, then quickly fall to the ground, like influenza.

颠覆了成见

数十年以来，公共健康官员指定政策都是基于这一假设：病毒通过两种途径传播，要么是通过空气，如麻疹和结核，或者是重的潮湿的飞沫，通过嘴和鼻子传播，仍后快速落到地面，如流感。

Today it's clear that the coronavirus — and all respiratory viruses — spread through a combination of droplets and aerosols, said Dr. Michael Klompas, a professor at Harvard Medical School and infectious disease doctor.

哈佛大学感染科教授说，今天人们清楚：冠状病毒和所有的呼吸道病毒，都可以通过飞沫和气溶胶传播。

这一发现为室内通风提供了理论依据。

详见：https://edition.cnn.com/2022/03/18/health/research-benefits-from-covid-19-khn-partner/index.html